Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).

被引：0
|
作者：
Stilgenbauer, S [1 ]
Winkler, D [1 ]
Kröber, A [1 ]
Kienle, D [1 ]
Hallek, M [1 ]
Hensel, M [1 ]
Lengfelder, E [1 ]
Trümper, L [1 ]
Dreger, P [1 ]
Jäger, U [1 ]
Döhner, H [1 ]
机构：
[1] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
478
引用
收藏
页码：140A / 140A
页数：1
相关论文
共 50 条
  • [41] Prognostic factors predicting disease progression in early (Binet stage A) chronic lymphocytic leukemia (CLL):: First analysis of the CLL1-protocol of the German CLL Study Group (GCLLSG).
    Schmitt, B
    Busch, R
    Kuhn-Hallek, I
    Bergmann, M
    Wendtner, CM
    Nerl, C
    Bosse, D
    Jäger, U
    Eckart, M
    Sezer, O
    Schmid, P
    Wilhelm, M
    Blau, I
    Döhner, H
    Hiddemann, W
    Emmerich, B
    Hallek, M
    BLOOD, 2000, 96 (11) : 371A - 371A
  • [42] Fludarabine, mitoxantrone and cyclophosphamide combination therapy in relapsed chronic lymphocytic leukemia (CLL) with or without G-CSF: Results of the first interim ananlysis of a phase III study of the German CLL study group (GCLLSG).
    Schmitt, BF
    Franke, A
    Burkhard, O
    Schlag, R
    Hopfinger, G
    Stauch, M
    Bergmann, M
    Wendtner, CM
    Busch, R
    Emmerich, B
    Hallek, N
    BLOOD, 2002, 100 (11) : 364B - 364B
  • [43] VH mutation status and genomic aberrations in the prospective CLL1 trial (Binet-A) of the German CLL Study Group (GCLLSG).
    Stilgenbauer, S
    Krober, A
    Winkler, D
    Kienle, D
    Busch, R
    Emmerich, B
    Hallek, M
    Dohner, H
    BLOOD, 2002, 100 (11) : 168A - 168A
  • [44] Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG)
    Cramer, P.
    von Tresckow, J.
    Bahlo, J.
    Robrecht, S.
    Al-Sawaf, O.
    Langerbeins, P.
    Engelke, A.
    Fink, A. -M.
    Fischer, K.
    Tausch, E.
    Seiler, T.
    von Weikersthal, Fischer L.
    Hebart, H.
    Kreuzer, K. -A.
    Ritgen, M.
    Kneba, M.
    Wendtner, C. -M.
    Stilgenbauer, S.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 24 - 24
  • [45] Incidence and outcome of Richter transformation in chronic lymphocytic leukaemia (CLL) - A meta-analysis of German CLL Study Group (GCLLSG) trials
    Al-Sawaf, O.
    Robrecht, S.
    Bahlo, J.
    Fink, A. M.
    Cramer, P.
    Langerbeins, P.
    von Tresckow, J.
    Maurer, C.
    Kutsch, N.
    Lange, E.
    Kiehl, M.
    Fischer, K.
    Stilgenbauer, S.
    Wendtner, C-M
    Goede, V
    Hallek, M.
    Eichhorst, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 166 - 166
  • [46] Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
    Al-Sawaf, O.
    Robrecht, S.
    Bahlo, J.
    Fink, A. M.
    Cramer, P.
    Von Tresckow, J.
    Lange, E.
    Kiehl, M.
    Dreyling, M.
    Ritgen, M.
    Duerig, J.
    Tausch, E.
    Schneider, C.
    Stilgenbauer, S.
    Wendtner, C. M.
    Fischer, K.
    Goede, V
    Hallek, M.
    Eichhorst, B.
    LEUKEMIA, 2021, 35 (01) : 169 - 176
  • [47] Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
    O. Al-Sawaf
    S. Robrecht
    J. Bahlo
    A. M. Fink
    P. Cramer
    J. v Tresckow
    E. Lange
    M. Kiehl
    M. Dreyling
    M. Ritgen
    J. Dürig
    E. Tausch
    C. Schneider
    S. Stilgenbauer
    C. M. Wendtner
    K. Fischer
    M. Goede
    B. Hallek
    Leukemia, 2021, 35 : 169 - 176
  • [48] Evaluation or clinical prognostic factors for progression-free survival in patients with B-CLL in stage binet A: An interim report from the CLL1 protocol of the German CLL study group (GCLLSG).
    Fingerle-Rowson, G
    Busch, R
    Schmitt, B
    Wendtner, C
    Bergmann, M
    Kuhn-Hallek, I
    Vehling-Kaiser, U
    Jager, U
    Eckart, M
    Nerl, C
    Emmerich, B
    Hallek, M
    BLOOD, 2002, 100 (11) : 358B - 358B
  • [49] Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
    Kutsch, Nadine
    Fink, Anna Maria
    Federhen, Anno
    Giza, Adam
    Robrecht, Sandra
    Stumpf, Janina
    Stoltefuss, Andrea
    Vehling-Kaiser, Ursula
    Koenigsmann, Michael
    Tausch, Eugen
    Schneider, Christof
    Stilgenbauer, Stephan
    Illmer, Thomas
    Schlag, Rudolf
    Doerfel, Steffen
    Gaska, Tobias
    Kiehl, Michael G.
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2022, 140 : 9879 - 9881
  • [50] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Fuerstenau, Moritz
    Robrecht, Sandra
    Giza, Adam
    Fink, Anna
    Fischer, Kirsten
    Langerbeins, Petra
    Al-Sawaf, Othman
    Tausch, Eugen
    Schneider, Christof
    Schetelig, Johannes
    Dreger, Peter
    Boettcher, Sebastian
    Kreuzer, Karl-Anton
    Schilhabel, Anke
    Brueggemann, Monika
    Kneba, Michael
    Wendtner, Clemens
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
12345